Antuan V. Tran

Antuan V. Tran

Auto-generated profile, based on publicly available information

Antuan V. Tran

Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FBFelipe Batalini
Felipe Batalini
DGDoga C. Gulhan
Doga C. Gulhan
VMVictor Mao
Victor Mao
ATAntuan Tran
Antuan Tran
MPMadeline Polak
Madeline Polak
GWGerburg Wulf
Gerburg Wulf
Purpose: The identification of patients with homologous recombination deficiency (HRD) beyond BRCA1/2 mutations is an urgent task, as they may benefit from PARP inhibitors. We have previously developed a method to detect mutational signature 3 (Sig3), termed SigMA, associated with HRD from clinical panel sequencing data, that is able to reliably detect HRD from the limited sequencing data derived from gene-focused panel sequencing. Experimental Design: We apply this method to patients from two independent datasets: (i) high-grade serous ovarian cancer and triple-negative breast cancer (TNBC) from a phase Ib trial of the PARP inhibitor olaparib in combination with the PI3K inhibitor buparlisib (BKM120; NCT01623349), and (ii) TNBC patients who received neoadjuvant olaparib in the phase II PETREMAC trial (NCT02624973). Results: We find that Sig3 as detected by SigMA is positively associated with improved progression-free survival and objective responses. In addition, comparison of Sig3 detection in panel and exome-sequencing data from the same patient samples demonstrated highly concordant results and superior performance in comparison with the genomic instability score. Conclusions: Our analyses demonstrate that HRD can be detected reliably from panel-sequencing data that are obtained as part of routine clinical care, and that this approach can identify patients beyond those with germline BRCA1/2mut who might benefit from PARP inhibitors. Prospective clinical utility testing is warranted.

29 September 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AMAdrian Marino-Enriquez
Adrian Marino-Enriquez
JNJan Philipp Novotny
Jan Philipp Novotny
DGDoga C. Gulhan
Doga C. Gulhan
IKIsabella Klooster
Isabella Klooster
ATAntuan V. Tran
Antuan V. Tran
JFJonathan Alfred Fletcher
Jonathan Alfred Fletcher
Purpose: Leiomyosarcoma (LMS) is an aggressive sarcoma for which standard chemotherapies achieve response rates under 30%. There are no effective targeted therapies against LMS. Most LMS are characterized by chromosomal instability (CIN), resulting in part from TP53 and RB1 co-inactivation and DNA damage repair defects. We sought to identify therapeutic targets that could exacerbate intrinsic CIN and DNA damage in LMS, inducing lethal genotoxicity. Experimental Design: We performed clinical targeted sequencing in 287 LMS and genome-wide loss-of-function screens in 3 patient-derived LMS cell lines, to identify LMS-specific dependencies. We validated candidate targets by biochemical and cell-response assays in vitro and in seven mouse models. Results: Clinical targeted sequencing revealed a high burden of somatic copy-number alterations (median fraction of the genome altered =0.62) and demonstrated homologous recombination deficiency signatures in 35% of LMS. Genome-wide short hairpin RNA screens demonstrated PRKDC (DNA-PKcs) and RPA2 essentiality, consistent with compensatory nonhomologous end joining (NHEJ) hyper-dependence. DNA-PK inhibitor combinations with unconventionally low-dose doxorubicin had synergistic activity in LMS in vitro models. Combination therapy with peposertib and low-dose doxorubicin (standard or liposomal formulations) inhibited growth of 5 of 7 LMS mouse models without toxicity. Conclusions: Combinations of DNA-PK inhibitors with unconventionally low, sensitizing, doxorubicin dosing showed synergistic effects in LMS in vitro and in vivo models, without discernable toxicity. These findings underscore the relevance of DNA damage repair alterations in LMS pathogenesis and identify dependence on NHEJ as a clinically actionable vulnerability in LMS.

1 April 2023
Verified
Other
Open access
FBFelipe Batalini
Felipe Batalini
DGDoga C. Gulhan
Doga C. Gulhan
VMVictor Mao
Victor Mao
ATAntuan Tran
Antuan Tran
MPMadeline Polak
Madeline Polak
GWGerburg Wulf
Gerburg Wulf
Purpose:The identification of patients with homologous recombination deficiency (HRD) beyond BRCA1/2 mutations is an urgent task, as they may benefit from PARP inhibitors. We have previously developed a method to detect mutational signature 3 (Sig3), termed SigMA, associated with HRD from clinical panel sequencing data, that is able to reliably detect HRD from the limited sequencing data derived from gene-focused panel sequencing.Experimental Design:We apply this method to patients from two independent datasets: (i) high-grade serous ovarian cancer and triple-negative breast cancer (TNBC) from a phase Ib trial of the PARP inhibitor olaparib in combination with the PI3K inhibitor buparlisib (BKM120; NCT01623349), and (ii) TNBC patients who received neoadjuvant olaparib in the phase II PETREMAC trial (NCT02624973).Results:We find that Sig3 as detected by SigMA is positively associated with improved progression-free survival and objective responses. In addition, comparison of Sig3 detection in panel and exome-sequencing data from the same patient samples demonstrated highly concordant results and superior performance in comparison with the genomic instability score.Conclusions:Our analyses demonstrate that HRD can be detected reliably from panel-sequencing data that are obtained as part of routine clinical care, and that this approach can identify patients beyond those with germline BRCA1/2mut who might benefit from PARP inhibitors. Prospective clinical utility testing is warranted.

1 April 2023
Verified
Other
Open access
FBFelipe Batalini
Felipe Batalini
DGDoga C. Gulhan
Doga C. Gulhan
VMVictor Mao
Victor Mao
ATAntuan Tran
Antuan Tran
MPMadeline Polak
Madeline Polak
GWGerburg Wulf
Gerburg Wulf
Supplementary Table from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

1 April 2023
Verified
Other
Open access
FBFelipe Batalini
Felipe Batalini
DGDoga C. Gulhan
Doga C. Gulhan
VMVictor Mao
Victor Mao
ATAntuan Tran
Antuan Tran
MPMadeline Polak
Madeline Polak
GWGerburg Wulf
Gerburg Wulf
Supplementary Table from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

17 December 2025
Verified
Other
Open access
AMAdrian Marino-Enriquez
Adrian Marino-Enriquez
JNJan Philipp Novotny
Jan Philipp Novotny
DGDoga C. Gulhan
Doga C. Gulhan
IKIsabella Klooster
Isabella Klooster
ATAntuan V. Tran
Antuan V. Tran
JFJonathan Alfred Fletcher
Jonathan Alfred Fletcher
Supplementary Table S5: Molecular features of patient-derived LMS models from Champions Oncology used in in vivo validation studies (five LMS PDX), including clinical and morphological features of LMS tumors from which they were derived.